Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Nutrients ; 16(14)2024 Jul 14.
Artigo em Inglês | MEDLINE | ID: mdl-39064713

RESUMO

(1) Background: Proglucagon-derived peptides (PDGPs) including glucagon (Gcg), GLP-1, and GLP-2 regulate lipid metabolism in the liver, adipocytes, and intestine. However, the mechanism by which PGDPs participate in alterations in lipid metabolism induced by high-fat diet (HFD) feeding has not been elucidated. (2) Methods: Mice deficient in PGDP (GCGKO) and control mice were fed HFD for 7 days and analyzed, and differences in lipid metabolism in the liver, adipose tissue, and duodenum were investigated. (3) Results: GCGKO mice under HFD showed lower expression levels of the genes involved in free fatty acid (FFA) oxidation such as Hsl, Atgl, Cpt1a, Acox1 (p < 0.05), and Pparα (p = 0.05) mRNA in the liver than in control mice, and both FFA and triglycerides content in liver and adipose tissue weight were lower in the GCGKO mice. On the other hand, phosphorylation of hormone-sensitive lipase (HSL) in white adipose tissue did not differ between the two groups. GCGKO mice under HFD exhibited lower expression levels of Pparα and Cd36 mRNA in the duodenum as well as increased fecal cholesterol contents compared to HFD-controls. (4) Conclusions: GCGKO mice fed HFD exhibit a lesser increase in hepatic FFA and triglyceride contents and adipose tissue weight, despite reduced ß-oxidation in the liver, than in control mice. Thus, the absence of PGDP prevents dietary-induced fatty liver development due to decreased lipid uptake in the intestinal tract.


Assuntos
Antígenos CD36 , Dieta Hiperlipídica , Absorção Intestinal , Metabolismo dos Lipídeos , Fígado , Camundongos Knockout , PPAR alfa , Proglucagon , Animais , Masculino , Dieta Hiperlipídica/efeitos adversos , PPAR alfa/metabolismo , PPAR alfa/genética , Fígado/metabolismo , Proglucagon/metabolismo , Proglucagon/genética , Antígenos CD36/metabolismo , Antígenos CD36/genética , Camundongos , Esterol Esterase/metabolismo , Esterol Esterase/genética , Triglicerídeos/metabolismo , Camundongos Endogâmicos C57BL , Ácidos Graxos não Esterificados/metabolismo , Peptídeo 1 Semelhante ao Glucagon/metabolismo , Duodeno/metabolismo , Carnitina O-Palmitoiltransferase/metabolismo , Carnitina O-Palmitoiltransferase/genética , Tecido Adiposo/metabolismo , Gorduras na Dieta , Peptídeo 2 Semelhante ao Glucagon/metabolismo , Aciltransferases , Lipase
2.
Neurol Int ; 16(3): 653-662, 2024 Jun 11.
Artigo em Inglês | MEDLINE | ID: mdl-38921953

RESUMO

The tau protein is a microtubule-associated protein that promotes microtubule stabilization. The phosphorylation of the tau protein has been linked to its dissociation from microtubules. Here, we examined the relationship between neuronal depolarization activity and tau protein phosphorylation by employing model systems in culture as well as in vivo. The KCl-evoked depolarization of cultured neurons has often been used to investigate the effects of neuronal activity. We found dephosphorylation at AT8 sites (S202, T205), T212, AT180 sites (T231, S235), and S396 in KCl-simulated cultured neurons. We also found that the KCl-induced tau protein dephosphorylation increases the level of the tau protein fractionated with stable microtubules. In an in vivo experiment, we demonstrated that the exposure of mice to a new environment activates protein phosphatase 1 in the mouse hippocampus and induces tau protein dephosphorylation. We also found an increased amount of the tau protein in a stable microtubule fraction, suggesting that the dephosphorylation of the tau protein may lead to its increased microtubule association in vivo. These results suggest that the association of microtubules with tau proteins may be regulated by the tau protein phosphorylation status affected by neuronal electrical activity.

3.
Endocr J ; 71(5): 499-514, 2024 May 23.
Artigo em Inglês | MEDLINE | ID: mdl-38462511

RESUMO

We investigated the impact of the Coronavirus disease 2019 (COVID-19) pandemic on the management of endocrine and metabolic disorders in Japan. We conducted a cross-sectional nationwide questionnaire survey targeting board-certified endocrinologists under the auspices of the Japan Endocrine Society. The questionnaire consisted of multiple-choice questions and open-ended responses. Out of approximately 2,700 specialists, 528 (19.5%) opted to participate, suggesting a high level of interest in COVID-19 management among endocrinologists. The study found that almost half of participants had encountered cases of endocrine and metabolic disorders following COVID-19 infection or vaccination. Conditions related to thyroid diseases, glucose metabolism disorders/diabetes, and hypothalamic-pituitary disorders were particularly prevalent. Diabetes and obesity were identified as having high rates of severe cases or fatalities due to COVID-19. The study also highlighted challenges in routine diagnosis and treatment, emphasizing the potential benefits of combining remote consultations with in-person visits to optimize the frequency of examinations and check-ups during infectious disease outbreak which disrupts access to healthcare providers. The insights obtained from this survey are expected to contribute to ensuring appropriate healthcare provision for patients with endocrine and metabolic disorders by using flexible consultation formats, particularly even in the conditions where medical access may be limited due to future outbreaks of emerging or re-emerging infectious diseases.


Assuntos
COVID-19 , Doenças do Sistema Endócrino , Doenças Metabólicas , SARS-CoV-2 , Humanos , COVID-19/epidemiologia , Japão/epidemiologia , Estudos Transversais , Doenças Metabólicas/epidemiologia , Doenças do Sistema Endócrino/epidemiologia , Doenças do Sistema Endócrino/terapia , Inquéritos e Questionários , Feminino , Masculino , Sociedades Médicas , Endocrinologistas , Adulto , Pessoa de Meia-Idade , Endocrinologia/organização & administração , Padrões de Prática Médica/estatística & dados numéricos
4.
Neurosci Res ; 205: 40-46, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-38508957

RESUMO

Sleep apnea is regarded as an important risk factor in the pathogenesis of Alzheimer disease (AD). Chronic intermittent hypoxia treatment (IHT) given during the sleep period of the circadian cycle in experimental animals is a well-established sleep apnea model. Here we report that transient IHT for 4 days on AD model mice causes Aß overproduction 2 months after IHT presumably via upregulation of synaptic BACE1, side-by-side with tau hyperphosphorylation. These results suggest that even transient IHT may be sufficient to cause long-lasting changes in the molecules measured as AD biomarkers in the brain.


Assuntos
Peptídeos beta-Amiloides , Modelos Animais de Doenças , Síndromes da Apneia do Sono , Proteínas tau , Animais , Proteínas tau/metabolismo , Fosforilação , Peptídeos beta-Amiloides/metabolismo , Síndromes da Apneia do Sono/metabolismo , Síndromes da Apneia do Sono/fisiopatologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Hipóxia/metabolismo , Doença de Alzheimer/metabolismo , Encéfalo/metabolismo , Secretases da Proteína Precursora do Amiloide/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA